Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab, Orelabrutinib, and Bortezomib in High-Risk MCL
NCT06656221Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06656221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656221.